According to a recent report, “The Cancer Paradox: Oncologists’ Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring,” oncologists believe they are seeing more and more patients with advanced cancers, and that screening barriers are the leading reason why. They worry that current tests may not catch cancer recurrence early enough.
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.
Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.
Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.
University of Oklahoma researchers have discovered one reason why the brain tumor glioblastoma is so aggressive.
Dxcover Limited on April 30 announced the presentation of real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.
A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a phase III clinical trial by researchers at City of Hope.
Pfizer Inc. on April 26 announced results from the pivotal phase III CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard-of-care Bacillus Calmette-Guérin as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.
An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab (Keytruda) added to standard-of-care therapy improved survival for patients with locally advanced head-and-neck cancer.
Johnson & Johnson on April 26 announced new data from cohort 2 of the pivotal phase IIB SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer.
